1mg, best e pharmacy in India

ARIXTRA 2.5 MG/0.5ML INJECTION

generic_icon
MRP: Rs. 680 for 1 vial(s) (0.5 ML injection each)
1
Unfortunately, we don't have any more items in stock
Report Error

Composition for ARIXTRA

Fondaparinux(2.5 mg/0.5ml)

food interaction for ARIXTRA

alcohol interaction for ARIXTRA

pregnancy interaction for ARIXTRA

lactation interaction for ARIXTRA

food
alcohol
pregnancy
lactation
It can be taken with or without food, but it is better to take Arixtra 2.5 mg/0.5ml injection at a fixed time.
Interaction with alcohol is unknown. Please consult your doctor.
Arixtra 2.5 mg/0.5ml injection is probably safe to use during pregnancy.
Animal studies have shown low or no adverse effect on the foetus, however, there are limited human studies. Please consult your doctor.
PROBABLY SAFE
Unknown. Human and animal studies are not available. Please consult your doctor.

SALT INFORMATION for ARIXTRA

Fondaparinux(2.5 mg/0.5ml)

Uses

Arixtra 2.5 mg/0.5ml injection is used to prevent deep vein thrombosis (blood clot in deep veins) and pulmonary embolus (blood clot in lungs).

How it works

Arixtra 2.5 mg/0.5ml injection prevents the formation of harmful blood clots.

Common side effects

Pale colored skin, Facial swelling, Allergic reaction, Skin rash, Bruise, Bleeding, Blisters on skin, Burning sensation, Itching, Confusion, Dark red spots under the skin, Dizziness, Shortness of breath, Injection site bruising, Injection site bleeding, Insomnia, Urticaria

Common Dosage for ARIXTRA 2.5 MG/0.5ML INJECTION

Patients taking ARIXTRA 2.5 MG/0.5ML INJECTION

  • 92%
    Once A Day
  • 8%
    Once A Week

SUBSTITUTES for ARIXTRA

No substitutes found

Top Cardiologists

  • Dr. Rajneesh Kapoor
    MBBS, MD, DNB
    5
  • Dr. Balbir Singh
    MBBS, MD, DM, Fellowship, Fellowship
    4.8
  • Dr. R. R. Kasliwal
    MBBS, MD, DM, Fellowship
    4.7
  • Dr. Manjinder Sandhu
    MBBS, MD, DNB, DM, Fellowship, Fellowship
    4.7
  • Dr. Sumeet Sethi
    MBBS, DNB, DM
    4.6

Expert advice for ARIXTRA

  • Do not take fondaparinux, if you are allergic to fondaparinux or any of the other ingredients.
  • Doctor’s advice should be considered in case of patients with following history of disease conditions: high blood pressure, stroke, kidney or liver problems, stomach ulcers, or bleed easily; diabetes; or obesity.
  • Consult your doctor before using fondaparinux, if you are an elderly patient (above 75 years of age).
  • Avoid using fondaparinux, if you are pregnant or breast feeding.

Frequently asked questions for ARIXTRA

Fondaparinux

Q.How does fondaparinux work?
Fondaparinux belongs to a class of medication called anti-coagulants. It is used for patients who are about to have certain kinds of surgery as well as to prevent clots in the legs (deep vein thrombosis) and lungs (pulmonary embolism). It works by preventing one of the steps of blood clotting thus preventing formation of new clots as well as worsening of the existing clots

Q.Is fondaparinux dialyzable?
Fondaparinux is added to the tube leaving the body during dialysis and hence is dialyzable

Q.Does it affect INR?
INR (international normalized ratio) shows how long it takes for blood to clot when on anticoagulant therapy versus no therapy. Fondaparinux therapy increases INR to 2-3

Q.Is fondaparinux derived pork?
It is not derived from pork but people allergic to pork should not take fondaparinux

Q.Is fondaparinux the same as heparin or lmwh?
Fondaparinux is not the same as heparin orlmwh(low molecular weight heparin)

Q.Is it an anti-coagulant?
Fondaparinux is not the same as heparin or lmwh (low molecular weight heparin) but all of them belong to the same class of medication called anti-coagulants

Q.Is fondaparinux FDA approved for hit?
Fondaparinux is not approved by the FDA for HIT (heparin induced thrombocytopenia)

Q.Does it cause hyperkalemia?
Hyperkalemia i.e. increase in potassium levels in blood may be one of the uncommon side effects of fondaparinux

Q.Is it reversible?
Fondaparinux treatment is not reversible.

Articles


Content on this page was last updated on 28 July, 2015, by Dr. Varun Gupta (MD Pharmacology)